Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Number (%) of On-treatment and post-treatment AEs and SAEs

From: Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

  FP/SAL 250/50 μg (N = 314) SAL 50 μg (N = 325)
AEs (on-treatment) 185 (59) 205 (63)
COPD 47 (15) 51 (16)
Headache 19 (6) 19 (6)
Upper respiratory tract infection 15 (5) 20 (6)
Back pain 10 (3) 13 (4)
Diarrhea 11 (4) 10 (3)
Edema peripheral 6 (2) 14 (4)
Nausea 5 (2) 13 (4)
Treatment-related AEs (on-treatment) 19 (6) 22 (7)
AEs leading to withdrawal from study 29 (9) 33 (10)
SAEs (on-treatment) 75 (24) 82 (25)
SAEs (post-treatment) 16 (5) 8 (2)
Fatal SAEs (on-treatment) 4 (1) 3 (<1)
Pneumonia AEs (all) 13 (4) 10 (3)
  1. Adverse events occurring in ≥2% of patients in either treatment group shown. AE = adverse event; COPD = chronic obstructive pulmonary disease; FP = fluticasone propionate; SAE = serious adverse event; SAL = salmeterol.